Clinical Research Directory
Browse clinical research sites, groups, and studies.
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Sponsor: Chong Kun Dang Pharmaceutical
Summary
The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.
Official title: A Prospective, Multicenter, Open-Label, Randomized, Comparative, Phase 4 Trial to Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2025-08-14
Completion Date
2030-12
Last Updated
2025-04-24
Healthy Volunteers
No
Conditions
Interventions
Everolimus
Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit
Mycophenolate mofetil Tablet/Capsule
Up to 1.5g BID(total 3g daily), PO
Locations (1)
Samsung Medical Center
Seoul, Seoul, South Korea